Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101955 | 0.85 | SMN1; SMN2 (0.42) | MAPTGAAL3MBTL1POLBNPSR1 | |
| SCHEMBL10101729 | 0.85 | L3MBTL1 (0.43) | MAPTGAAL3MBTL1POLBAGXT | |
| SCHEMBL10101728 | 0.78 | MAPT (0.39) | MAPTGAAL3MBTL1POLBAGXT | |
| SCHEMBL15251323 | 0.72 | HTT (0.42) | MAPTGAANPSR1 | |
| SCHEMBL10101751 | 0.72 | L3MBTL1 (0.43) | MAPTGAAL3MBTL1POLBAGXT | |
| SCHEMBL10101769 | 0.71 | S1PR1 (0.42) | MAPTGAAL3MBTL1POLBS1PR1 | |
| SCHEMBL10101922 | 0.71 | SMN1; SMN2 (0.43) | MAPTGAAPOLBS1PR1NPSR1 | |
| SCHEMBL10102111 | 0.71 | SMN1; SMN2 (0.43) | MAPTGAAPOLBS1PR1NPSR1 | |
| SCHEMBL10101753 | 0.68 | MAPK1 (0.41) | MAPTGAAL3MBTL1POLBS1PR1 | |
| SCHEMBL9945411 | 0.67 | L3MBTL1 (0.47) | MAPTGAAL3MBTL1POLBAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | MAPT 2433/4885GAA 2110/4885L3MBTL1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.